<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Innov Aging</journal-id><journal-id journal-id-type="iso-abbrev">Innov Aging</journal-id><journal-id journal-id-type="publisher-id">innovateage</journal-id><journal-title-group><journal-title>Innovation in Aging</journal-title></journal-title-group><issn pub-type="epub">2399-5300</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">6840573</article-id><article-id pub-id-type="doi">10.1093/geroni/igz038.1573</article-id><article-id pub-id-type="publisher-id">igz038.1573</article-id><article-categories><subj-group subj-group-type="heading"><subject>Session 2215 (Paper)</subject><subj-group subj-group-type="category-toc-heading"><subject>Dementia and Cognitive Impairment</subject></subj-group></subj-group></article-categories><title-group><article-title>TREATMENT WITH ANTIPSYCHOTICS AND RISK OF DEATH IN 58,000 PATIENTS FROM SWEDISH DEMENTIA REGISTRY</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Religa</surname><given-names>Dorota</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Schwertner</surname><given-names>Emilia</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Garcia-ptacek</surname><given-names>sara</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Johansson</surname><given-names>Bjorn</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>N&#x000e4;gga</surname><given-names>Katarina</given-names></name><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Winblad</surname><given-names>Bengt</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Eriksdotter</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Secnik</surname><given-names>Juraj</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib></contrib-group><aff id="AF0001"><label>1</label>
<institution>Karolinska Institutet</institution>, Stockholm, Sweden</aff><aff id="AF0002"><label>2</label>
<institution>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#x000f6;, Lund University</institution>, Malm&#x000f6;, Malm&#x000f6;, Sweden</aff><pub-date pub-type="collection"><month>11</month><year>2019</year></pub-date><pub-date pub-type="epub" iso-8601-date="2019-11-08"><day>08</day><month>11</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>08</day><month>11</month><year>2019</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>3</volume><issue>Suppl 1</issue><issue-title>Program Abstracts from the GSA 2019 Annual Scientific Meeting &#x0201c;Strength in Age&#x02014;Harnessing the Power of Networks&#x0201d;</issue-title><fpage>S421</fpage><lpage>S421</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2019. Published by Oxford University Press on behalf of The Gerontological Society of America.</copyright-statement><copyright-year>2019</copyright-year><license license-type="cc-by" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="igz038.1573.pdf"/><abstract><title>Abstract</title><p>Background: Behavioral and Psychological symptoms of Dementia (BPSD) are a heterogeneous group of clinical phenomena that is subjectively experienced by the patient and/or observable by an examiner (e.g., caregiver, physician) consisting in disturbed emotions, perception, thought, motor activity, and altered personality. There are recommendations to limit antipsychotic use in patients with dementia, and the big educational effort is made to follow them. In Sweden antipsychotics use changed from 10.1% in 2007-2008 to 5.2% in 2014-2015. Aims: The aim of the study is to analyze the actors associated with treatment and mortality of dementia patients, particularly those suffering from BPSD. Particularly we focus on assessing all-cause mortality patients with dementia treated with antipsychotic drugs (APDs). Methods: We have analyzed 58,412 patients newly diagnosed with dementia. We have found that 2526 of the patients were prescribed APDs (602 typical APDs and 1833 atypical APDs)- Results In the adjusted models, use of APDs at the time of dementia diagnosis was associated with increased mortality risk in the total cohort (hazard ratio = 1.4; 95% confidence interval 1.3-1.5). We have also stratified the results. Conclusions: The risk of death in patients with dementia was increased in group that used atypical and typical APDs. Our study gives more evidence to advice caution in APD prescription for patients with dementia.</p></abstract><counts><page-count count="1"/></counts></article-meta></front></article>